1
|
Vecchio D, Puricelli C, Malucchi S, Virgilio E, Martire S, Perga S, Passarelli F, Valentino P, Di Sapio A, Cantello R, Dianzani U, Comi C. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients. Mult Scler Relat Disord 2024; 82:105412. [PMID: 38198989 DOI: 10.1016/j.msard.2023.105412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 12/25/2023] [Indexed: 01/12/2024]
Abstract
BACKGROUND Neurofilament light chains (NfL) are cytoskeletal biomarkers of axonal damage, about 40-fold higher in cerebrospinal fluid (CSF) compared to serum, and requiring ultrasensitive techniques to be measured in this latter fluid. OBJECTIVES To compare CSF and serum NfL levels in multiple sclerosis (MS) patients using different platforms. METHODS 60 newly diagnosed relapsing-remitting MS patients (38 females; median age: 36.5 years, range: 15-60) were enrolled before steroid or disease-modifying treatments. CSF and serum NfL were measured with: the commercial Ella™ microfluidic platform (Bio-Techne), the Lumipulse™ Chemiluminescent Enzyme ImmunoAssay (Fujirebio), and the SIMOA™ on the SR-X instrument using NF-light assays (Quanterix). RESULTS CSF and serum NfL absolute levels strongly correlated between assays, although being more elevated with Ella™. Passing-Bablok regression showed high agreement in measuring CSF NfL between assays (with greater proportional difference using Ella™), and very high agreement for serum comparing SIMOA™ and Lumipulse™. Similarly, the Bland-Altman comparison evidenced lower biases for Lumipulse™ for both fluids. CONCLUSIONS CSF and serum NfL in naïve MS patients are reliably measured with all assays. Although not interchangeable, SIMOA™ and Lumipulse™ showed high agreement for serum and CSF values.
Collapse
Affiliation(s)
- D Vecchio
- Neurology Unit, Department of Translational Medicine, Maggiore della Carità University Hospital, University of Piemonte Orientale, Corso Mazzini 18, Novara 28100, Italy.
| | - C Puricelli
- Clinical Biochemistry Laboratory, Department of Health Sciences, Maggiore della Carità University Hospital, University of Piemonte Orientale, Novara, Italy
| | - S Malucchi
- Neurology Unit, CRESM University Hospital San Luigi Gonzaga, Orbassano, Italy
| | - E Virgilio
- Neurology Unit, Department of Translational Medicine, Maggiore della Carità University Hospital, University of Piemonte Orientale, Corso Mazzini 18, Novara 28100, Italy
| | - S Martire
- Neuroscience Institute Cavalieri Ottolenghi (NICO) and CRESM Biobank, University Hospital San Luigi Gonzaga, Orbassano, Italy
| | - S Perga
- Clinical Biochemistry Laboratory, Department of Health Sciences, Maggiore della Carità University Hospital, University of Piemonte Orientale, Novara, Italy
| | - F Passarelli
- Clinical Biochemistry Laboratory, Department of Health Sciences, Maggiore della Carità University Hospital, University of Piemonte Orientale, Novara, Italy
| | - P Valentino
- Clinical Biochemistry Laboratory, Department of Health Sciences, Maggiore della Carità University Hospital, University of Piemonte Orientale, Novara, Italy
| | - A Di Sapio
- Neurology Unit, CRESM University Hospital San Luigi Gonzaga, Orbassano, Italy
| | - R Cantello
- Neurology Unit, Department of Translational Medicine, Maggiore della Carità University Hospital, University of Piemonte Orientale, Corso Mazzini 18, Novara 28100, Italy
| | - U Dianzani
- Clinical Biochemistry Laboratory, Department of Health Sciences, Maggiore della Carità University Hospital, University of Piemonte Orientale, Novara, Italy
| | - C Comi
- Neurology Unit, Department of Translational Medicine, Maggiore della Carità University Hospital, University of Piemonte Orientale, Corso Mazzini 18, Novara 28100, Italy
| |
Collapse
|
2
|
Pizzamiglio C, Strigaro G, Barbero P, Tondo G, Magistrelli L, Rovellotti C, Comi C, Cantello R. 11. Excessive inhibitory visuomotor connections in Parkinson’s disease with freezing of gait. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2017.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Ferrari M, Comi C, Marino F, Magistrelli L, De Marchi F, Cantello R, Riboldazzi G, Bono G, Cosentino M. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients. Eur J Clin Pharmacol 2016; 72:1335-1341. [PMID: 27497990 DOI: 10.1007/s00228-016-2111-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 07/26/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND Visual hallucinations (VHs) are frequent non-motor complication of Parkinson's disease (PD), associated to a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and psychosis in Alzheimer's disease, addictions, schizophrenia, and bipolar disorder. However, there are only a few studies on DR variants and VHs in PD, which did not provide conclusive results. OBJECTIVES The present study aimed to determine whether genetic differences of DR are associated with visual hallucinations (VHs) in a cohort of Parkinson's disease (PD) patients. METHODS A case-control study of 84 PD subjects, 42 with and 42 without VHs,that were matched for age, gender, disease duration, and dopaminergic medication was conducted. Polymerase chain reaction for SNPs in both D1-like (DRD1A-48G [rs4532] and C62T [rs686], DRD5T798C [rs6283]) and D2-like DR (DRD2G2137A [rs1800497] and C957T [rs6277], DRD3G25A [rs6280] and G712C [rs1800828], DRD4C616G [rs747302] and nR VNTR 48bp) analyzed genomic DNA. RESULTS Patients carrying allele T at DRD1C62T had an increased risk of VHs, expressed as OR (95 % CI, p value), of 10.7 (2.9-40, p = 0.0001). Moreover, patients with DRD1-48 GG and 62TT genotype displayed shorter time to VHs, whereas a longer time to VHs was found in subjects carrying the DRD4 CG alleles. CONCLUSIONS PD patients with VHs display higher frequency of DR SNPs associated with increased D1-like activity and decreased D2-like activity. Our data are in line with associations reported in other neurodegenerative and psychiatric conditions. Results likely provide valuable information for personalizing pharmacological therapy in PD patients.
Collapse
Affiliation(s)
- M Ferrari
- Center of Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100, Varese, Italy.
| | - C Comi
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - F Marino
- Center of Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100, Varese, Italy
| | - L Magistrelli
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - F De Marchi
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - R Cantello
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - G Riboldazzi
- Departments of Biotechnology and Life Science, University of Insubria, Varese, Italy
| | - G Bono
- Departments of Biotechnology and Life Science, University of Insubria, Varese, Italy
| | - M Cosentino
- Center of Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100, Varese, Italy
| |
Collapse
|
4
|
Comi C, Magistrelli L, Oggioni GD, Carecchio M, Fleetwood T, Cantello R, Mancini F, Antonini A. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism Relat Disord 2014; 20:1329-34. [PMID: 25457816 DOI: 10.1016/j.parkreldis.2014.10.010] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 10/08/2014] [Accepted: 10/10/2014] [Indexed: 11/17/2022]
Abstract
BACKGROUND In recent years, non-motor features of Parkinson's disease (PD) have received increasing attention and PD is currently considered a systemic rather than a pure basal ganglia disorder. Among the systemic features, peripheral neuropathy (PN) is a recent acquisition since the first case-control study reporting increased frequency of PN in PD dates back to 2008. METHODS We reviewed available literature on peripheral nervous system (PNS) involvement in PD. RESULTS Evidence of α-synuclein deposition in the PNS and small nerve fiber deterioration in both drug-naïve and treated PD patients is becoming stronger. In addition, several recent reports documented a significant role of levodopa exposure together with group B vitamin deficiency in facilitating the development of PN and case reports suggested that treatment with continuous levodopa intestinal infusion may increase the risk of acute PN compared to both oral levodopa and other dopaminergic treatments. CONCLUSION It is currently debated whether PN is an intrinsic disease-related feature, a consequence of levodopa treatment or both. In this review, we will discuss the different hypotheses, as well as our perspective on open issues and controversies.
Collapse
Affiliation(s)
- C Comi
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy; Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy.
| | - L Magistrelli
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy
| | - G D Oggioni
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy
| | - M Carecchio
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy
| | - T Fleetwood
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy
| | - R Cantello
- Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Eastern Piedmont, "Amedeo Avogadro", Novara, Italy
| | - F Mancini
- Parkinson's Disease and Movement Disorders Centre, Neurology Unit, San Pio X Clinic, Fondazione Opera San Camillo, Milan, Italy
| | - A Antonini
- Parkinson's Disease and Movement Disorders Unit, IRCCS Ospedale San Camillo, Venice, Italy
| |
Collapse
|
5
|
Lochner P, Cantello R, Brigo F, Coppo L, Nardone R, Tezzon F, Raymkulova O, Strigaro G, Comi C, Leone MA. Transorbital sonography in acute optic neuritis: a case-control study. AJNR Am J Neuroradiol 2014; 35:2371-5. [PMID: 25034772 DOI: 10.3174/ajnr.a4051] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Acute unilateral optic neuritis is associated with a thickening of the retrobulbar portion of the optic nerve as revealed by transorbital sonography, but no comparison has been made between nerve sheath diameter and optic nerve diameter in patients with acute optic neuritis versus healthy controls. We evaluated optic nerve sheath diameter and optic nerve diameter in patients with acute optic neuritis and healthy controls and compared optic nerve sheath diameter and optic nerve diameter with visual-evoked potentials in patients. MATERIALS AND METHODS A case-control study was performed in 2 centers. Twenty-one consecutive patients with onset of visual loss during the prior 10 days and established acute noncompressive unilateral optic neuritis were compared with 21 healthy controls, matched for sex and age (±5 years). Two experienced vascular sonographers performed the study by using B-mode transorbital sonography. Visual-evoked potentials were performed on the same day as the transorbital sonography and were evaluated by an expert neurophysiologist. Sonographers and the neurophysiologist were blinded to the status of the patient or control and to clinical information, including the side of the affected eye. RESULTS The median optic nerve sheath diameter was thicker on the affected side (6.3 mm; interquartile range, 5.9-7.2 mm) compared with the nonaffected side (5.5 mm; interquartile range, 5.1-6.2 mm; P < .0001) and controls (5.2 mm; interquartile range, 4.8-5.5 mm; P < .0001). The median optic nerve diameter was 3.0 mm (range, 2.8-3.1 mm) on the affected side and 2.9 mm (range, 2.8-3.1 mm) on the nonaffected side (P = not significant.). Both sides were thicker than those in controls (2.7 mm; interquartile range, 2.5-2.8 mm; P = .001 and .009). No correlation was found between optic nerve sheath diameter and optic nerve diameter and amplitude and latency of visual-evoked potentials in patients with optic neuritis. CONCLUSIONS Transorbital sonography is a promising tool to support the clinical diagnosis of acute optic neuritis. Further studies are needed to define its specific role in the diagnosis and follow-up of optic neuritis.
Collapse
Affiliation(s)
- P Lochner
- From the Department of Neurology (P.L., F.B., F.T.), General Hospital, Merano, Italy Section of Neurology (P.L., R.C., L.C., G.S., C.C.), Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro," Novara, Italy
| | - R Cantello
- Section of Neurology (P.L., R.C., L.C., G.S., C.C.), Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro," Novara, Italy
| | - F Brigo
- From the Department of Neurology (P.L., F.B., F.T.), General Hospital, Merano, Italy Department of Neurological and Movement Sciences (F.B.), Section of Clinical Neurology, University of Verona, Verona, Italy
| | - L Coppo
- Section of Neurology (P.L., R.C., L.C., G.S., C.C.), Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro," Novara, Italy
| | - R Nardone
- Department of Neurology (R.N.), Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria
| | - F Tezzon
- From the Department of Neurology (P.L., F.B., F.T.), General Hospital, Merano, Italy
| | - O Raymkulova
- Head and Neck Department (O.R.), SCDU Neurology, MS Centre, AOU "Maggiore della Carità," Novara, Italy
| | - G Strigaro
- Section of Neurology (P.L., R.C., L.C., G.S., C.C.), Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro," Novara, Italy
| | - C Comi
- Section of Neurology (P.L., R.C., L.C., G.S., C.C.), Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro," Novara, Italy Interdisciplinary Research Center of Autoimmune Diseases (C.C., M.A.L.), Novara, Italy
| | - M A Leone
- Interdisciplinary Research Center of Autoimmune Diseases (C.C., M.A.L.), Novara, Italy
| |
Collapse
|
6
|
Abstract
Fas is a transmembrane receptor involved in the death program of several cell lines, including T lymphocytes. Deleterious mutations hitting genes involved in the Fas pathway cause the autoimmune lymphoprolipherative syndrome (ALPS). Moreover, defective Fas function is involved in the development of common autoimmune diseases, including autoimmune syndromes hitting the nervous system, such as multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP). In this review, we first explore some peculiar aspects of Fas mediated apoptosis in the central versus peripheral nervous system (CNS, PNS); thereafter, we analyze what is currently known on the role of T cell apoptosis in both MS and CIDP, which, in this regard, may be seen as two faces of the same coin. In fact, we show that, in both diseases, defective Fas mediated apoptosis plays a crucial role favoring disease development and its chronic evolution.
Collapse
Affiliation(s)
- C Comi
- Department of Clinical and Experimental Medicine, Section of Neurology, Amedeo Avogadro University, Novara, Italy.
| | | | | |
Collapse
|
7
|
Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, De Paoli L, Cantello R, Gaidano G, Monaco F. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep 2011; 2011:2011/apr15_1/bcr1120103549. [PMID: 22701032 DOI: 10.1136/bcr.11.2010.3549] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
A patient with multiple myeloma was treated with high-dose chemotherapy followed by two autologous bone marrow transplantations (ABMTs). Nine months after the second ABMT the patient complained of severe left hemiparesis, paraesthesias, left homonymous visual field defects and gait ataxia. She was diagnosed with progressive multifocal leucoencephalopathy (PML) confirmed by detection of JC virus (JCV) DNA and prescribed cidofovir every other week and mirtazapine daily. Her symptoms and signs remained stable and after 6 months the JCV DNA was undetectable in the cerebrospinal fluid. Repeated MRI scans demonstrated the stabilisation of demyelinating lesion volume; after more than 2 years of follow-up the patient's neurological examination does not show significant variations. Combination of cidofovir and mirtazapine may be helpful in the treatment of PML in HIV-negative patients.
Collapse
Affiliation(s)
- P Ripellino
- Department of Neurology, University of Turin, Turin, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:306-8. [PMID: 20639381 DOI: 10.1136/jnnp.2009.188912] [Citation(s) in RCA: 96] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND A few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). OBJECTIVE To analyse the efficacy of rituximab in a large CIDP cohort. METHODS A retrospective, observational and multicentre study on the use of rituximab in CIDP. 13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders. RESULTS Nine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1-6) and lasted for a median period of 1 year (range, 1-5). CONCLUSIONS Rituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occurring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.
Collapse
Affiliation(s)
- L Benedetti
- Department of Neurology, Osp. S. Andrea, Via Vittorio Veneto 197, 19100 La Spezia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann S, Matà S, Mazzeo A, Sabatelli M, Nobile-Orazio E. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2009; 17:289-94. [PMID: 19863650 DOI: 10.1111/j.1468-1331.2009.02802.x] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- D Cocito
- Dipartimento di Neuroscienze, AOU San Giovanni Battista, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Durelli L, Rolla S, Conti L, Clerico M, Contessa G, Ripellino P, La Puma D, Viglietta E, Uccelli A, Zaffaroni M, Cavalla P, Rinaldi L, Comi C, Novelli F. FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β. J Neurol Sci 2009. [DOI: 10.1016/s0022-510x(09)70355-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun 2008; 9:438-44. [PMID: 18496551 DOI: 10.1038/gene.2008.35] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Perforin is involved in cell-mediated cytotoxicity and mutations of its gene (PRF1) cause familial hemophagocytic lymphohistiocytosis (FLH2). PRF1 sequencing in 190 patients with multiple sclerosis and 268 controls detected two FLH2-associated variations (A91V, N252S) in both groups and six novel mutations (C999T, G1065A, G1428A, A1620G, G719A, C1069T) in patients. All together, carriers of these variations were more frequent in patients than in controls (phenotype frequency: 17 vs 9%, P=0.0166; odds ratio (OR)=2.06, 95% confidence interval (CI): 1.13-3.77). Although A91V was the most frequent variation and displayed a trend of association with multiple sclerosis (MS) in the first population of patients and controls (frequency of the 91V allele: 0.076 vs 0.043, P=0.044), we used it as a marker to confirm PRF1 involvement in MS and assessed its frequency in a second population of 966 patients and 1520 controls. Frequency of the 91V allele was significantly higher in patients than in controls also in the second population (0.075 vs 0.058%, P=0.019). In the combined cohorts of 1156 patients and 1788 controls, presence of the 91V allele in single or double dose conferred an OR=1.38 (95% CI=1.10-1.74). These data suggest that A91V and possibly other perforin variations indicate susceptibility to MS.
Collapse
Affiliation(s)
- G Cappellano
- Department of Medical Sciences, Interdisciplinary Research Center of Autoimmune Diseases, A Avogadro University of Eastern Piedmont, Novara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Galimberti D, Fenoglio C, Comi C, Scalabrini D, De Riz M, Leone M, Venturelli E, Cortini F, Piola M, Monaco F, Bresolin N, Scarpini E. MDC/CCL22 intrathecal levels in patients with multiple sclerosis. Mult Scler 2008; 14:547-549. [DOI: 10.1177/1352458507084268] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
MDC/CCL22 has been detected in the brain of mice with experimental autoimmune encephalomyelitis. MDC/CCL22 cerebrospinal fluid levels were evaluated in 56 patients with multiple sclerosis (MS) and in 17 controls. No significant differences were found, even when stratifying patients according to the disease subtype. Stratifying by gender, significantly increased MDC/CCL22 levels were observed in female patients when compared with female controls and male patients (109.03 versus 98.54 and 99.37 pg/mL, P = 0.034 and 0.018, respectively). Therefore, MDC/CCL22 is likely to play a role in the development of MS in females only, possibly influencing the intracerebral recruitment of Th2 cells, which produce anti-inflammatory cytokines. Multiple Sclerosis 2008; 14: 547—549. http://msj.sagepub.com
Collapse
Affiliation(s)
- D. Galimberti
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy,
| | - C. Fenoglio
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - C. Comi
- Department of Neurology, Ospedale Maggiore, University 'Amedeo Avogadro', Novara, Italy, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD) and Department of Medical Sciences, 'A. Avogadro' University of Eastern Piedmont, Novara, Italy
| | - D. Scalabrini
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - M. De Riz
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - M. Leone
- Department of Neurology, Ospedale Maggiore, University 'Amedeo Avogadro', Novara, Italy
| | - E. Venturelli
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - F. Cortini
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - M. Piola
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - F. Monaco
- Department of Neurology, Ospedale Maggiore, University 'Amedeo Avogadro', Novara, Italy, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD) and Department of Medical Sciences, 'A. Avogadro' University of Eastern Piedmont, Novara, Italy
| | - N. Bresolin
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - E. Scarpini
- Department of Neurological Sciences, 'Dino Ferrari' Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| |
Collapse
|
13
|
Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur J Neurol 2007; 14:162-7. [PMID: 17250724 DOI: 10.1111/j.1468-1331.2006.01629.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
CXCL10 (interferon-gamma-inducible protein-10) levels are increased in cerebrospinal fluid of multiple sclerosis (MS) patients with symptomatic attacks of inflammatory demyelination, supporting a role for this molecule in MS pathogenesis. Two hundred and twenty-six patients with MS and 235 controls were genotyped for G --> C and T --> C single nucleotide polymorphisms (SNPs) in exon 4 of CXCL10 gene. Haplotypes were tested for association and correlated with clinical variables. The two SNPs studied were in complete linkage disequilibrium. None of the determined haplotypes was associated with MS. However, carriers of the GGTT haplotype (defined as wild type, according to the sequence in National Centre for Biotechnology Information (NCBI) database) had a significantly lower progression index than non-carriers (P = 0.016). Furthermore, amongst patients who had an initial relapsing remitting (RR) course of the disease, the time between onset and second episode was significantly longer in GGTT carriers (P = 0.021). Considering secondary progressive (SP)-MS patients, the time between the initial RR form and the subsequent worsening to SP was longer in this group (P = 0.08). Therefore, the GGTT haplotype of the CXCL10 gene is not a susceptibility factor for the development of MS, but is probably to influence the course of MS, possibly contributing to slow down the progression of the disease.
Collapse
Affiliation(s)
- D Galimberti
- Department of Neurological Sciences, Dino Ferrari Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
BACKGROUND In the nineties, there has been evidence that motor evoked potential (MEP) studies might improve the diagnosis of psychogenic paralysis. OBJECTIVE To review a series of patients (1986-1999) who finally had a diagnosis of psychogenic paralysis at our Institutions. To detect if, over that period, the time taken to make the diagnosis had changed, and, if so, this had any relationship to the diagnostic tests used or to other variables. METHODS We selected a patient sample (n=21) seen by the same team of neurologists, whose diagnostic criteria were homogeneously based on the DSM IV, and who were studied with MEPs. We analysed their clinical features, the type and timing of the investigations done, and the time taken to make the diagnosis. These variables acted as the dependent factors in a Multivariate Analysis of Variance (MANOVA) model, in which the year of observation was the fixed factor. RESULTS The diagnosis was 50% earlier in the period 1993 to 1999 (10 patients) than in the period 1986-1992 (11 patients) (F = 28.3, p < 0.0001). The only associated change was an earlier MEP study (F=18.4, p < 0.0001), which invariably showed normal findings. CONCLUSION MEP studies contributed to speed up the diagnosis of psychogenic paralysis. Possibly, normal MEPs rendered the neurologist confident about the physiological integrity of motor fibers in the corticospinal tract, anterior roots and plexuses. Such integrity, if nerve trunks and muscles are intact, and in the appropriate diagnostic context, implies a psychogenic cause for paralysis.
Collapse
Affiliation(s)
- R Cantello
- Clinica Neurologica, Ospedale Maggiore, Novara, Italy.
| | | | | | | | | |
Collapse
|
15
|
Comi C, Leone M, Bonissoni S, DeFranco S, Bottarel F, Mezzatesta C, Chiocchetti A, Perla F, Monaco F, Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000; 55:921-7. [PMID: 11061245 DOI: 10.1212/wnl.55.7.921] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Fas (CD95) triggers programmed cell death and is involved in shutting off the immune response. Inherited deleterious mutations hitting Fas or its signaling pathway cause autoimmune/lymphoproliferative syndrome (ALPS). OBJECTIVE To assess the possibility that decreased Fas function plays a role in development of MS. METHODS The authors evaluated Fas function in long-term T cell lines (21 days of culture) from 32 patients with relapsing-remitting MS (RRMS), 15 with secondary progressive MS (SPMS), and 15 with primary progressive MS (PPMS) by assessing cell survival upon Fas triggering by monoclonal antibodies (Mab). RESULTS Fas-induced cell death was significantly lower in all patient groups than in controls, and lower in SPMS than in RRMS. Moreover, 8/15 patients with PPMS, 10/15 with SPMS, and 8/32 with RRMS were frankly resistant to Fas. Frequency of resistance to Fas-induced cell death was significantly higher in all patient groups than in controls (2/75), and higher in SPMS than in RRMS. The findings that the parents of two Fas-resistant patients were Fas-resistant and that fusion of T cells from two Fas-resistant patients with Fas-sensitive HUT78 cells gave rise to Fas-resistant hybrid lines suggest that Fas-resistance is due to inherited alterations of the Fas signaling pathway, with production of molecules exerting a dominant negative effect on a normal Fas system. CONCLUSIONS Defects of the immune response shutting-off system may be involved in the pathogenesis of MS, particularly in its progressive evolution.
Collapse
Affiliation(s)
- C Comi
- Neurological Clinic, Department of Medical Science, University of Eastern Piedmont, Novara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|